Creating new materials to improve CAR-T cell therapy production
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production
This study is exploring a new way to help your body make CAR-T cells right where you need them, which could make treatment for blood cancers quicker, easier, and more effective for you.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11062479 on NIH RePORTER |
What this research studies
This research focuses on developing biomaterial scaffolds that can enhance the production of CAR-T cells directly within the body, rather than relying on lengthy and costly laboratory procedures. By using these innovative materials, the goal is to streamline the manufacturing process, reduce costs, and improve the effectiveness of CAR-T cell therapy for patients with blood cancers. The approach aims to generate CAR-T cells in situ, which could lead to faster treatment times and better patient outcomes. Patients may benefit from a more efficient and accessible form of CAR-T therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with blood cancers who are considering CAR-T cell therapy.
Not a fit: Patients with solid tumors or those who are not eligible for CAR-T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the costs and improve the accessibility of CAR-T cell therapy for patients with blood cancers.
How similar studies have performed: While there have been advancements in CAR-T cell therapy, the specific approach of using biomaterial scaffolds for in situ production is relatively novel and has not been extensively tested.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Brudno, Yevgeny — Univ of North Carolina Chapel Hill
- Study coordinator: Brudno, Yevgeny
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.